Evidence map›Paper›PMID 39917338›Full record

ArticleFrontiers in pediatrics2025

Atypical hemolytic uremic syndrome with a

Masato Ando, Kazuo Kubota, Saori Kadowaki, Minako Kawamoto, Norio Kawamoto, Haruka Okamoto, Soichiro Nagaya, Yuki Miwa, Hidenori Ohnishi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masato AndoDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Kazuo KubotaDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Saori KadowakiDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Minako KawamotoDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Norio KawamotoDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Haruka OkamotoGifu University Advanced Critical Care Center, Gifu, Japan.
Soichiro NagayaGifu University Advanced Critical Care Center, Gifu, Japan.
Yuki MiwaDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Hidenori OhnishiDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, and is caused by overactivation of the alternative complement pathway. A 13-year-old Japanese boy with an unremarkable medical history developed symptoms of TMA following coronavirus disease 2019 (COVID-19) infection with mild respiratory symptoms. He was eventually diagnosed with aHUS with a gain-of-function

Indexed as

alternative complement pathwayatypical hemolytic uremic syndromeGOF C3 variantinborn errors of immunitysevere acute respiratory syndrome coronavirus 2

Identifiers

PMID39917338
PMCPMC11799235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.